Shots:
- Novavax has entered into a non-exclusive license agreement with Pfizer for the use of Novavax’s Matrix-M adjuvant with Pfizer’s products in up to two disease areas
- As per the deal, Novavax will supply Matrix-M for $30M upfront, ~$500M in development & sales milestones, & tiered high mid-single-digit % royalties on product sales
- Pfizer will be solely responsible for the development & commercialization of its Matrix-M-based products
Ref: Novavax | Image: Novavax & Pfizer | Press Release
Related News: Madrigal Pharmaceuticals Broadens MASH Pipeline with Pfizer’s Ervogastat Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
